Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025Expert Review of Clinical Pharmacology

Current and emerging pharmacological treatment options for patients with dry eye disease

View Full Paper
Ask AI
Bookmark
Share

Authors

FCFeyza CukurovaGCGiulia CocoFLFilippo Lixi

Discussion

Loading...

Member takes

Overview

This review highlights current and emerging pharmacological options for dry eye disease, indicating novel delivery methods and mechanism-specific therapies.

Key Points

  • Current pharmacological treatments for dry eye disease include novel delivery platforms that enhance ocular bioavailability.
  • Innovative therapies are emerging, such as the recently FDA-approved TRPM8 agonist AR-15512 for symptomatic and disease modification.
  • The review emphasizes multimodal strategies addressing various disease mechanisms related to dry eye disease.
  • Advancements in drug formulations, including preservative-free emulsions, are crucial for improving treatment adherence and reducing side effects.

Cite This Study

Cukurova et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d03e1https://doi.org/10.1080/17512433.2025.2543380
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease2024 · 25 citations
  2. 2Redefining Dry Eye Disease Management: Emerging Pharmacologic and Device-Based Therapies in the Era of Precision Care: A Narrative Review2026
  3. 3The Evolving Landscape of Dry Eye Disease Therapies2024
  4. 4Advances in dry eye disease: from immunopathological mechanisms to emerging ophthalmic drug delivery systems2026 · 3 citations
  5. 5Bridging Therapeutics and Nanotechnology in Dry Eye Disease: A Review of Risk Factors, Drug Delivery Barriers, and Recent and Future Endeavors for Disease Management2026